SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

NEC Bio Presents Phase I/II NECVAX-NEO1 Trial Results at ESMO 2026

NEC Bio is presenting Phase I/II results from a trial of its individualized oral neoantigen therapy, NECVAX-NEO1, combined with checkpoint inhibitors and chemotherapy for patients with triple-negative breast cancer.

SquawkNews Desk

Related stories

Microsoft Restores Services After Global Outage Microsoft said services had fully recovered across Teams, Outlook, Copilot and other applications, ending an outage that disrupted online communications for businesses and governme M impact | EQUITY | Nov 14, 2026, 06:49 AM UTC Microsoft Says All Services Restored After Global Outage Microsoft said all services were restored after a global outage. M impact | EQUITY | Nov 14, 2026, 06:49 AM UTC Microsoft says outage issue addressed and remaining service restored Microsoft says it completed efforts to address the underlying issue and restored service to remaining impacted customers and regions. M impact | EQUITY | Nov 14, 2026, 06:37 AM UTC Microsoft Completes Outage Fix, Restores Service to Remaining Customers Microsoft says it completed efforts to address the underlying issue and restored service to remaining impacted customers and regions. L impact | EQUITY | Nov 14, 2026, 06:37 AM UTC Microsoft Says Consumer Services Recovered, Enterprise Recovery Ongoing Microsoft said its consumer products services had fully recovered at 4:10 p.m. UTC Friday, while Microsoft 365 enterprise services were seeing some sustained recovery. The company M impact | EQUITY | Nov 14, 2026, 05:32 AM UTC Microsoft Says Consumer Products Services Recovered Microsoft said its consumer products services had fully recovered, while Microsoft 365 enterprise services were seeing a sustained recovery. M impact | EQUITY | Nov 14, 2026, 05:17 AM UTC